

GLP-1 & GIP Receptor Agonists

Class/Main Action	Name	Dose Range	Considerations
GLP-1 Receptor Agonist (GLP-1 RA) “Incretin Mimetic” <ul style="list-style-type: none"> Increases insulin release with food Slows gastric emptying Promotes satiety Suppresses glucagon 	exenatide (Byetta)	5 and 10 mcg BID	Side effects for all: Nausea, vomiting, weight loss, injection site reaction. Report signs of acute pancreatitis (severe abdominal pain, vomiting), stop med. Increase dose monthly to achieve targets. Black box warning: Thyroid C-cell tumor warning (avoid if family history of medullary thyroid tumor). *Significantly reduces risk of CV death, heart attack, and stroke. †Approved for pediatrics 10-17 yrs Lowers A1c 0.5 – 1.6% Weight loss: 4-6% body weight loss.
	exenatide XR [†] (Bydureon)	2 mg 1x a week Pen injector - Bydureon BCise	
	liraglutide (Victoza)* [†]	0.6, 1.2 and 1.8 mg daily	
	dulaglutide* (Trulicity)	0.75, 1.5, 3.0 and 4.5 mg 1x a week pen injector	
	lixisenatide (Adlyxin)	10 mcg 1x a day for 14 days 20 mcg 1x day starting day 15	
	semaglutide* (Ozempic)	0.25, 0.5, 1.0 and 2.0 mg 1x a week pen injector	
Dual Incretin Agonist Combines both GLP-1 and GIP Incretins. Same action profile as GLP-1 RA, with more intensive action profile.	(Rybelsus) Oral tablet	3, 7, and 14 mg daily in a.m. Take on empty stomach w/H2O sip	
	Tirzepatide (Mounjaro)	2.5, 5.0, 7.5, 10, 12.5 and 15 mg 1x a week prefilled single dose pen Increase dose by 2.5 mg once monthly to reach targets.	Side effects include: Nausea, diarrhea, injection site reactions. Avoid if family history medullary thyroid tumor. Report pancreatitis. Lowers A1C ~ 1.8 - 2.4% Weight loss: 7-13% body weight loss at max dose.

Insulin/Injectable Combos

PocketCards updated annually. Download FREE
CDCES Coach App for latest updates and notifications.



Name	Combines	Considerations
IDegLira* Xultophy 100/3.6	Insulin degludec (IDeg or Tresiba) Ultra long insulin + Liraglutide (Victoza) GLP-1 Receptor Agonist (GLP-1 RA)	Xultophy 100/3.6 pre-filled pen = 100 units IDeg / 3.6 mg liraglutide per mL Once daily injection – Dose range 10 to 50 = 10 – 50 units IDeg + 0.36 -1.8 mg liraglutide Recommended starting dose: <ul style="list-style-type: none">• 16 IDegLira (= 16 units IDeg + 0.58 mg liraglutide) Titrate dose up or down by 2 units every 3-4 days to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 21 days.
iGlarLixi* Soliqua 100/33	Insulin glargine (Lantus) Basal Insulin + Lixisenatide (Adlyxin) GLP-1 Receptor Agonist	Soliqua 100/33 Solostar Pen = 100 units glargine / 33 µg lixisenatide per mL Once daily injection an hour prior to first meal of day. Dose range 15 – 60 = 15-60 units glargine + 5 – 20µg lixisenatide Recommended starting dose: <ul style="list-style-type: none">• 15 units if not meeting glucose target on 30 units basal insulin or GLP-1 RA• 30 units if not meeting glucose target on 30-60 units basal insulin or GLP-1 RA Titrate dose up or down by 2-4 units every week to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 14 days.

***Discontinue basal insulin /GLP-1 RA therapy before starting. If dose missed, resume with next usual scheduled dose.**

Observe precautions of each component drug.